Clinical Trial

The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of BCMA CAR-T（S103） in the treatment of refractory, generalized myasthenia gravis. The study is a dose escalation trial in adult, refractory, systemic MG patients. A total of 6-24 MG patients who meet the inclusion criteria are expected to be recruited.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-27.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-05-22
Trial Details
NCT Number NCT06958939
Lead Sponsor Ting Chang, MD
Collaborators: Hebei Senlang Biotechnology Co., LTD
Conditions Myasthenia Gravis, Generalized
Enrollment 10 participants
Start Date 2025-05-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-27